Oxford Biomedica. 2005 to see 'Huge value creation' (Panmure Gordon)

It is interesting that A Oxford Parma Company Avidex has a Agreement with Active Biotech .



What I can gather they use a different approach to target the 5t4 .
But nonetheless less what I found interesting was the increased efficacy of the trial and toxicity indications targeting the 5t4 .
To my mind this bodes well for Trovax .